IP Library › Granted Patent US 9,856,221
Granted Patent B2
US 9,856,221 · App. 15/308,439 · Granted Jan 2, 2018

Salt of ivabradine and process for the preparation thereof

Inventors: Michael Lynch (Saint Jean de la Ruelle, FR); Patrick Cointepas (Saint Jean de la Ruelle, FR); David Lafargue (Saint Jean le Blanc, FR); Gilles Briault (Saint Peravy Epreux, FR)
Assignee: LES LABORATOIRES SERVIER
C07D223/16C07C65/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,856,221
App. No.
15/308,439
Granted
Jan 2, 2018
Kind
B2
Abstract

Ivabradine hemipamoate of formula (I): and its hydrates. Medicinal products containing the same which are useful in the treatment or prevention of the various clinical situations of myocardial ischaemia such as angina pectoris, myocardial infarction and the associated rhythm disturbances, as well as in the various pathologies involving rhythm disturbances, especially supraventricular rhythm disturbances, and in systolic or diastolic heart failure.

Claims (6)

1. Ivabradine hemipamoate of formula (I):

2. A process for the preparation of ivabradine hemipamoate according to claim 1 , wherein ivabradine hydrochloride is brought together with sodium pamoate in an aqueous medium in a proportion ivabradine hydrochloride/sodium pamoate of from 1/0.5 to 1/0.6, to form ivabradine hemipamoate of formula (I), which ivabradine hemipamoate is then extracted from the aqueous medium by means of an organic solvent, followed by removal of the solvent under vacuum, to yield ivabradine hemipamoate.

3. A pharmaceutical composition comprising as active ingredient ivabradine hemipamoate according to claim 1 , in combination with one or more inert, non-toxic, pharmaceutically acceptable excipients or carriers.

4. A method of treating a condition selected from the group consisting of clinical situations of myocardial ischaemia; pathologies involving rhythm disturbances; and systolic or diastolic heart failure, in a subject in need thereof, comprising administration of an effective amount of ivabradine hemipamoate according to claim 1 , alone or in combination with one or more inert, non-toxic, pharmaceutically acceptable excipients or carriers.

5. The method of claim 4 , wherein the condition is selected from the group consisting of angina pectoris and myocardial infarction and the associated rhythm disturbances.

6. The method of claim 4 , wherein the condition is a pathology involving supraventricular rhythm disturbances.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2016
From: LYNCH, MICHAEL; COINTEPAS, PATRICK; LAFARGUE, DAVID; BRIAULT, GILLES
To: LES LABORATOIRES SERVIER
Reel/Frame 040608/0409 →
Priority Claims (1)
FR 14 54081 · May 6, 2014 · national
Continuity (1)
Related Publication 20170050932A1 · Feb 23, 2017